Biohaven initiates enrollment in Phase 3 clinical trial of troriluzole

Biohaven Pharmaceutical has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in Spinocerebellar Ataxia, or SCA. Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. Currently, there are no FDA-approved treatments and there is no cure for SCA. Biohaven expects to enroll approximately 230 patients in this trial across approximately 22 sites in the United States. Researchers will evaluate the efficacy and safety of troriluzole over 48 weeks in patients with a diagnosis of SCA Types 1, 2, 3, 6, 7, 8, and 10. The primary outcome measure is the change in a patient’s score on the Modified Functional Scale for the Assessment and Rating of Ataxia.
https://thefly.com/landingPageNews.php?id=2879081